American Academy of Dermatology

10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring

Retrieved on: 
Monday, March 11, 2024
CSFS, PSFS, Biotechnology, Elective surgery, Bruise, Patient, SAN, Abdomen, American Academy, MD, Clinician, Clinical trial, American Academy of Dermatology, Erythema, ITT, FAAD, Pain, AAD, FDA, Organic acid, Edema, Annual general meeting, Pharmaceutical industry

SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101. An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.

Key Points: 
  • SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio , LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101.
  • An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.
  • "10XB101 has the appropriate product-market fit to capture the tremendous opportunity for submental contouring.
  • In addition, its attributes hold promise for potential expansion to other body contouring applications, such as treatment of the abdomen and flanks."

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Retrieved on: 
Monday, March 11, 2024
American Academy of Dermatology, Microbiota, Marketing, FDA, U.S. FDA, Skin, Forehead, Entrepreneurship, Risk, AAD, Safety, GI, Red, Rosacea, Minocycline, Patient, Clinical trial, Erythema, Vagina, Microbiology, American Academy

SCOTTSDALE, Ariz., March 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, announces that data from the Phase 1 clinical trial (DFD-29-CD-006) assessing the impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on the microbial flora of healthy adults were presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting that took place March 8-12, 2024, in San Diego, CA. The clinical trial also assessed the safety and tolerability of the treatment. The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical. DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy’s Laboratories Ltd.

Key Points: 
  • The clinical trial also assessed the safety and tolerability of the treatment.
  • The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical.
  • Microbiological samples were collected from the skin (forehead), stool and vagina at multiple timepoints through the study.
  • Additional information on the DFD-29 Phase 1 clinical trial can be found on ClinicalTrials.gov using the identifier NCT05597462 .

Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting 

Retrieved on: 
Monday, March 4, 2024
SAN, AAD, MHS, American Academy of Dermatology, Dermatology, MD, American Academy

SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, is excited to announce its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

Key Points: 
  • SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, is excited to announce its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
  • Dr. Gilly Munavalli, MD, MHS, FACMS will present Sofwave’s new Pure Impact™ Strength and Muscle Toning module to fellow dermatologists and meeting participants for the first time in the United States.
  • Sofwave Event Detail at AAD:

Dermavant Presents New Data on Treatment of Patients with Skin of Color from ADORING 1 and 2 Phase 3 Pivotal Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

Retrieved on: 
Friday, March 8, 2024
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, Skin, Week, Psoriasis, American Academy of Dermatology, FDA, Atopic dermatitis, Validation, Treatment, AAD, JD, White, Alaska Natives, American Indians, American Academy, Pharmaceutical industry

“Importantly, approximately 50% of patients who enrolled in the ADORING pivotal trials had skin of color, a particularly high representation in clinical trials.

Key Points: 
  • “Importantly, approximately 50% of patients who enrolled in the ADORING pivotal trials had skin of color, a particularly high representation in clinical trials.
  • Secondary endpoints in the pivotal studies included the proportion of patients who achieved ≥75% improvement in the Eczema Area and Severity Index (EASI75).
  • Baseline Demographics Across ADORING Pivotal Phase 3 Trials:
    Approximately 50% of patients who enrolled had skin of color.
  • New Data on VTAMA cream from ADORING 1 and ADORING 2 for the Treatment of AD in Patients with Skin of Color Presented at AAD 2024 – Primary and Secondary Endpoints:

LEO Pharma to Maintain Leadership Role at AAD in 2024 with New Late-Breaking Data Spanning Multiple Therapeutic Areas

Retrieved on: 
Wednesday, March 6, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Adolescence, EVP, American Academy of Dermatology, Ichthyosis, Atopic dermatitis, Pain, Dermatology, Calendar, Annual general meeting, AAD, Safety, Pharmacokinetics, Abstract, CHE, Congress, LEO, ASCEND, Leo Pharma, American Academy, Pharmaceutical industry

LEO Pharma A/S, a global leader in medical dermatology, will present a breadth of new data on moderate-to-severe chronic hand eczema (CHE), congenital ichthyosis (CI) and atopic dermatitis (AD) at the upcoming 82nd American Academy of Dermatology (AAD) Annual Meeting.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, will present a breadth of new data on moderate-to-severe chronic hand eczema (CHE), congenital ichthyosis (CI) and atopic dermatitis (AD) at the upcoming 82nd American Academy of Dermatology (AAD) Annual Meeting.
  • The event is being held from March 8th to 12th in San Diego, California.
  • “Our growing body of clinical evidence reinforces our passion and commitment to advancing the standard of care in medical dermatology,” said Kreesten Meldgaard Madsen, LEO Pharma’s Chief Development Officer.
  • I am proud that we can follow up on our 2023 AAD program with this level of critical data,” said Brian Hilberdink, EVP and President, Region North America, LEO Pharma.

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Monday, March 4, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Cream, American Academy of Dermatology, Safety, Randomness, Atopic dermatitis, Ageing, Autoimmunity, Treatment, Dermatology, Inflammation, AAD, Vitiligo, Prurigo, Hidradenitis suppurativa, Abstract, American Academy, Pharmaceutical industry

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.
  • “We are pleased to convene at this year’s AAD Annual Meeting and share data, including two late-breaking presentations, from our growing dermatology portfolio,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • “Our presence at this year’s meeting showcases Incyte’s commitment to find solutions for patients where there continues to be critical unmet needs.
  • They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2024.

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Retrieved on: 
Wednesday, March 6, 2024
ABBV, Psoriasis, American Academy of Dermatology, Research, FDA, Atopic dermatitis, AbbVie, XC, U.S. FDA, Dermatology, Skin, AAD, Safety, Risankizumab, Hyaluronic acid, Hidradenitis suppurativa, Abstract, Sleep, Patient, Science, Scalp, American Academy, Pharmaceutical industry

The presented data across AbbVie and Allergan Aesthetics' extensive portfolios reinforce the companies' ongoing commitment to developing transformative medical dermatology and aesthetic treatments to advance and redefine the standard of care for patients.

Key Points: 
  • The presented data across AbbVie and Allergan Aesthetics' extensive portfolios reinforce the companies' ongoing commitment to developing transformative medical dermatology and aesthetic treatments to advance and redefine the standard of care for patients.
  • The oral and poster presentations from AbbVie highlight efficacy, durability and safety data across the company's dermatology portfolio.
  • Select AbbVie and Allergan Aesthetics abstracts at AAD 2024 are outlined below.
  • The 2024 AAD Annual Meeting e-Posters are available here and late-breaking sessions are available here .

Medical Journal: Image-Guided Superficial Radiation Therapy Is Superior to Superficial Radiation Therapy Without Guidance

Retrieved on: 
Tuesday, February 20, 2024
Mohs surgery, Skin cancer, Freedom, Recurrence, Carcinoma, Toxicity, SRT, American Academy of Dermatology, Research, ASTRO, FDA, Skin, BCC, Radiation, SCC, NMSC, Society, Silverman, Patient, Histology, Photon, Radiation therapy, Cancer, American Academy, Medical imaging

BURR RIDGE, Ill., Feb. 20, 2024 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer, presented to dermatology patients as the GentleCure™ experience, announced the publication of research, "Image guidance improves freedom from recurrence in superficial radiation therapy for non-melanoma skin cancer," in Advances in Radiation Oncology, a peer-reviewed journal from the American Society for Radiation Oncology (ASTRO).

Key Points: 
  • It shows definitively that the new technology is superior, and represents a seminal moment in the care of skin cancer patients using radiation.
  • This study is the first to rigorously compare SRT to IGSRT, and it covers all the data that exists on IGSRT.
  • Superficial radiation therapy was developed over 100 years ago ( here ) and was the standard therapy for nonmelanoma skin cancer until Mohs micrographic surgery emerged in the 1930's ( here ).
  • IGSRT and the GentleCure experience will be showcased at the upcoming American Academy of Dermatology annual meeting in San Diego, at booth 3555.

Welcome to SciBase Capital Markets Day 2024

Retrieved on: 
Tuesday, January 9, 2024
NBC, Capital market, Science, MD, Skin, Karolinska Institute, Health, Rigel, AAD, Skin cancer, George Washington University, ABC, American Academy, SCIB, Worldwide Angel, Clinical, Government, Digital, Strategic planning, MIT, MBA, NYU, Fox, Congress, FDA, American Academy of Dermatology, Subway Series, CNN, Pinnacle, Publication

STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.

Key Points: 
  • STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.
  • During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals.
  • The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets.
  • Two external speakers will participate in the event, further supporting the US role in the SciBase strategy going forward.

Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Atopic Dermatitis

Retrieved on: 
Tuesday, November 28, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Safety, B cell, American Academy, Dermatitis, Patient, Atopic dermatitis, Therapy, American Academy of Dermatology, MRGPRX2, IL4, Escient, Skin, Pharmaceutical industry, EASE, Dermatology

By blocking activation of MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell mediated diseases with an initial focus on chronic urticaria (hives) and atopic dermatitis (eczema).

Key Points: 
  • By blocking activation of MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell mediated diseases with an initial focus on chronic urticaria (hives) and atopic dermatitis (eczema).
  • EP262 represents a novel, targeted approach to the treatment of these disorders with the potential for once-daily oral administration without the side effects observed with other approaches.
  • The study will evaluate clinical scores as well as histological and transcriptomic markers in lesional skin biopsies.
  • “With the initiation of our EASE clinical proof-of-concept study, we look forward to evaluating whether the promising preclinical findings with EP262 translate to patients with atopic dermatitis,” said Christian Weyer, M.D., M.A.S, Chief Medical Officer at Escient.